EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors associated with morbidity of totally implantable venous access device in patients with breast cancer

Burak Ilhan iD, Berkay Kiliç iD

Turkish Journal of Medical Sciences · 10.12.2024 · 54 (6) · 1230-1236

DOI: 10.55730/1300-0144.5904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 10.12.2024. Verfasst von Burak Ilhan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, Faculty of Medicine, İstanbul University, İstanbul, Turkiye. Hauptthemen laut MEDLINE: Breast Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: To investigate the possible morbidities associated with the implantation of a totally implantable venous access device (TIVAD) in breast cancer (BC) patients.Materials and methods: Clinical data and developed complications in 546 BC patients with TIVAD between 2017 and 2021 were analyzed retrospectively. Among these patients, 524 (96.0%) patients who underwent TIVAD implantation via the right subclavian vein (SCV) route were examined separately.

Results

The mean patient age was 56.1±11.4 years, and the mean patient body mass index was 25.3±6.5. The incidence of early complications was 2.3% (12 cases), and late complications were 2.6% (14 cases). Among these complications, 10 (1.9%) catheter-related infections developed more common than others. Early complications increased as the number of puncture attempts did and decreased with ultrasound guidance in the implantation, but no other predictive factors. There was no correlation between the patient's age, body mass index, BC side, puncture method, puncture number, surgical approach, radiotherapy, and late complications. There was no evidence that postoperative effects specific to BC surgery, such as increased pain, decreased functional capacity, and lymphedema, are altered with TIVAD implantation. For catheter-related infections only, adjuvant radiotherapy was a risk factor for patients with various comorbidities.

Conclusion

This study may conclude that the right SCV approach remains a morbidity-safe route for TIVAD implantation in BC patients, as in other malignancies. The study can only suggest clinicians use another implantation route to avoid catheter-related infection in patients scheduled for neoadjuvant treatment, who also have morbidity and are likely to receive postoperative radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultPostoperative ComplicationsCatheter-Related InfectionsCatheters, IndwellingCatheterization, Central VenousRisk FactorsMorbiditySubclavian Vein

Stichwörter der Autor:innen

Totally implantable venous access devicebreast cancermorbidityport catheter

Autor:innen und Institutionen

  • Division of General Surgery, Department of Surgery, Faculty of Medicine, İstanbul University, İstanbul, Turkiye.
  • Division of General Surgery, Department of Surgery, Institute of Oncology, İstanbul University, İstanbul, Turkiye.

ORCID-Profile: Burak Ilhan, Berkay Kiliç

Zitieren

APA

Ilhan, B., & Kiliç, B. (2024). Factors associated with morbidity of totally implantable venous access device in patients with breast cancer. Turkish Journal of Medical Sciences, 54(6), 1230-1236. https://doi.org/10.55730/1300-0144.5904

Vancouver

Ilhan B, Kiliç B. Factors associated with morbidity of totally implantable venous access device in patients with breast cancer. Turkish Journal of Medical Sciences. 2024;54(6):1230-1236. doi:10.55730/1300-0144.5904

BibTeX
@article{Ilhan2024,
  author = {Ilhan, Burak and Kiliç, Berkay},
  title = {Factors associated with morbidity of totally implantable venous access device in patients with breast cancer},
  journal = {Turkish Journal of Medical Sciences},
  year = {2024},
  volume = {54},
  number = {6},
  pages = {1230--1236},
  doi = {10.55730/1300-0144.5904}
}
Kostenlos starten →